Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on March 21, 2024. The filing addresses corporate governance and executive compensation matters rather than periodic financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the approval of a compensation plan.
Material Changes
On March 21, 2024, the Compensation Committee of the Board of Directors approved the 2024 Annual Cash Incentive Plan. Key provisions include:
- Eligible Officers: The Chief Executive Officer and Chief Financial Officer.
- Target Award: Determined as a percentage of each officer's 2024 base salary.
- Payout Range: Officers may earn between 0% and 150% of the target award amount.
- Performance Criteria: Payouts are contingent upon the achievement of pre-defined corporate financial objectives.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on market conditions, or specific risk factors beyond the standard disclosure of the compensation plan structure. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the specific base salary percentages used to calculate the target award amounts for the CEO and CFO.
- Review the detailed definition of the "pre-defined corporate financial objectives" to understand the performance hurdles.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual payout amounts realized under this plan.